EMA Authorised: Xeljanz (tofacitinib) — Pfizer Europe MA EEIG

View source ↗

Summary

EMA authorises Xeljanz (tofacitinib) for rheumatic arthritis under Pfizer Europe MA EEIG.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• XELJANZ (tofacitinib)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Rheumatoid. MAH: Pfizer Europe MA EEIG. Decision date: 27/11/2025